Analysts Set Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Price Target at $12.38

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) has been given a consensus rating of “Buy” by the five analysts that are presently covering the company, MarketBeat.com reports. Four equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $12.38.

Several analysts have recently weighed in on CRVS shares. StockNews.com downgraded Corvus Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, October 31st. HC Wainwright restated a “buy” rating and set a $11.00 target price on shares of Corvus Pharmaceuticals in a research note on Tuesday, January 14th. Finally, Oppenheimer raised their target price on Corvus Pharmaceuticals from $8.00 to $14.00 and gave the company an “outperform” rating in a research note on Wednesday, November 13th.

Hedge Funds Weigh In On Corvus Pharmaceuticals

Several large investors have recently modified their holdings of CRVS. Virtus ETF Advisers LLC bought a new position in Corvus Pharmaceuticals in the fourth quarter worth about $47,000. Nwam LLC bought a new position in Corvus Pharmaceuticals in the third quarter worth about $53,000. PKS Advisory Services LLC bought a new position in Corvus Pharmaceuticals in the fourth quarter worth about $56,000. Alpine Global Management LLC bought a new position in Corvus Pharmaceuticals in the fourth quarter worth about $62,000. Finally, ExodusPoint Capital Management LP bought a new position in Corvus Pharmaceuticals in the fourth quarter worth about $72,000. Institutional investors own 46.64% of the company’s stock.

Corvus Pharmaceuticals Price Performance

Shares of Corvus Pharmaceuticals stock opened at $4.19 on Friday. The business has a 50-day moving average of $5.21 and a 200-day moving average of $6.06. The company has a market capitalization of $269.24 million, a PE ratio of -4.51 and a beta of 1.07. Corvus Pharmaceuticals has a 1-year low of $1.30 and a 1-year high of $10.00.

Corvus Pharmaceuticals Company Profile

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.